Gene

BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, April 1, 2024
Neuroprotection, Research, Conference, Prejudice, Disease, SPA, ALS, Patient, Biomarker, Committee, Gene, MD, Biologics license application, Agency, Safety, Brainstorm, Poster, Therapy, Marketing, FDA, BLA, Episcopal conference, Food, Pharmaceutical industry

NEW YORK, April 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • NEW YORK, April 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.
  • We continue to believe that, if approved, NurOwn has the potential to be a valuable treatment option for ALS patients in need.
  • Stacy Lindborg, Ph.D., co-CEO BrainStorm commented, "We are acutely aware of the challenges faced by those afflicted with ALS.
  • In October 2023, Brainstorm announced a strategic realignment to enable accelerated development of NurOwn for the treatment of ALS.

FIRST STUDY USING BIOMIMETIC AI DIGITAL TWINS AND MULTIOMICS IN GENETICS RESEARCH

Retrieved on: 
Friday, March 29, 2024
Knowledge, Digital Insight, Biomimetics, Gene, Algorithm, Innovation, RKE, Knowledge engineering, Molecular diagnostics, Biomedical Research, Bias, Journal, Research, DNA, NAS, Phenotype, VUS, Brigham and Women's Hospital, Harvard University, Hospital, MUC20, Medical device

In addition to identifying pathogenic DNA variants the research also identified four VUSs potentially associated with the development of endometrial-related disorders.

Key Points: 
  • In addition to identifying pathogenic DNA variants the research also identified four VUSs potentially associated with the development of endometrial-related disorders.
  • "This landmark study demonstrated a way to combine omics and a digital twin ecosystem to understand the molecular mechanism of disease better.
  • In January, Life Sciences Review Magazine awarded RYLTI Top Biomimetic AI Platform of 2024 for its biomimetic AI digital twin ecosystem innovation, hailing the technology for opening new doors to discovery and accelerating the innovation process.
  • "The NAS has described the importance of using digital twins in biomedical research, which requires a toolset without limitations or bias for effective discovery and validation," said Joseph Glick, an award-winning biomimetic AI pioneer and Co-founder/Chief Innovation Officer of RYLTI.

Data-Science-Powered Research by Seattle Children's and Microsoft Shows Promise of Predicting SIDS and Other Causes of Sudden Death

Retrieved on: 
Thursday, March 28, 2024
Gene, Sudden death, Herbal cigarette, SIDS, Learning, Medical genetics, Child, Infant, Electronic cigarette, Oxygen, Rutgers University, Research institute, Microsoft, Partnership, Risk, International, Pediatrics, Death, Fatality, Seattle Children's, Preterm birth, Database, American Journal, Research, AI, University, Pregnancy, DRS, Cardiac arrest, Hypoxia, Genetic testing, Developing Story, Mortality, SUID, Doctor of Philosophy, Life, Smoking, Summit, Pacific Northwest, Medical device

The event was sponsored by The Center for Integrative Brain Research at Seattle Children's and Microsoft AI for Good Lab.

Key Points: 
  • The event was sponsored by The Center for Integrative Brain Research at Seattle Children's and Microsoft AI for Good Lab.
  • Among the many topics attendees discussed was groundbreaking new research that suggests genetic testing at birth may hold the promise of detecting SIDS risk — and potentially other causes of sudden death later in life.
  • The Aaron Matthew SIDS Research Foundation funds the database, which is maintained and managed at Seattle Children's Research Institute.
  • "Scientific research sometimes leads to surprises," said Jan-Marino Ramirez , PhD, Director of the Center for Integrative Brain Research at Seattle Children's.

Making Long-Term Memories Requires Nerve-Cell Damage

Retrieved on: 
Wednesday, March 27, 2024
Inflammation, Radulović, Psychiatry, Brain, TLR9, COVID, Gene, DNA repair, DSM-IV codes, Cell division, Genome instability, University Medical Center, Infection, Memory, Organelle, Hippocampus, Mouse, DNA, Albert Einstein, Nature, Cancer, Toll-like receptor 9, Neuron, Northwestern University, Doctor of Philosophy, Alzheimer's disease, Genome, Aarhus University, Cytoplasm, Cell, Dominic, B.A, Encephalitis, Ageing, Vaccine

"But our findings suggest that inflammation in certain neurons in the brain's hippocampal region is essential for making long-lasting memories."

Key Points: 
  • "But our findings suggest that inflammation in certain neurons in the brain's hippocampal region is essential for making long-lasting memories."
  • But looking more closely, we found, to our surprise, that TLR9 was activated only in clusters of hippocampal cells that showed DNA damage."
  • But in this population of hippocampal neurons, the DNA damage appeared to be more substantial and sustained.
  • Importantly, the researchers found that blocking the TLR9 inflammatory pathway in hippocampal neurons not only prevented mice from forming long-term memories but also caused profound genomic instability, i.e, a high frequency of DNA damage in these neurons.

Fosun International: Total Revenue for 2023 Reached RMB198.2 billion, Industrial Operation Profit Increased by 20% YoY

Retrieved on: 
Wednesday, March 27, 2024
Gene, Mining, PPT, Cell, RMB, Patient, Rehabilitation, TCFD, Marketing, World Health Organization, HSI, Artesunate, Carcinoma, MSCI, FTG, Telehealth, Lithium, National Medical Products Administration, HKEX, Sustainability, SCLC, AA, KOD, NMPA, Growth, Hope, Fosun Pharma, S&P, Task force, Club Med, Dragon

HONG KONG, March 27, 2024 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today announced its annual results for the year ended 31 December 2023 (the "Reporting Period").

Key Points: 
  • During the Reporting Period, the Group achieved a total revenue of RMB198.2 billion, representing a year-on-year increase of 8.6%.
  • Thanks to the Group's global business presence and continuous innovation, industrial operation profit reached RMB4.9 billion, representing a year-on-year increase of 20%.
  • Total revenue of the four core subsidiaries, namely Yuyuan, Fosun Pharma, Fosun Insurance Portugal and Fosun Tourism Group (FTG), was RMB142.69 billion, representing  a year-on-year increase of 8%, contributing 72% of the revenue.
  • In 2023, Fosun's overseas revenue reached RMB89.2 billion, representing a year-on-year growth of 6% and accounting for 45% of the total revenue.

Integrated DNA Technologies Unveils New Custom Vector Onboarding Tool to Optimize Gene Synthesis

Retrieved on: 
Wednesday, March 27, 2024
Genomics, Gene, Synthetic biology, Integration, IDT, Research, DNA, Confidentiality, IP, Integrated DNA Technologies

CORALVILLE, Iowa, March 27, 2024 /PRNewswire/ --Global genomics solutions provider Integrated DNA Technologies (IDT) is expanding its gene synthesis offerings with a new custom vector onboarding tool. The easy-to-use solution is designed for researchers who want to skip in-house cloning steps and move quickly into functional studies with 100% sequence-verified clonal DNA. By using IDT's new gene synthesis custom vector onboarding tool, researchers can submit their vector sequence via IDT's website without having to contact a sales representative, eliminating unnecessary back-and-forth emails.

Key Points: 
  • CORALVILLE, Iowa, March 27, 2024 /PRNewswire/ --Global genomics solutions provider Integrated DNA Technologies (IDT) is expanding its gene synthesis offerings with a new custom vector onboarding tool.
  • By using IDT's new gene synthesis custom vector onboarding tool, researchers can submit their vector sequence via IDT's website without having to contact a sales representative, eliminating unnecessary back-and-forth emails.
  • To see IDT's new custom vector onboarding tool, visit https://www.idtdna.com/genes .
  • IDT's new custom onboarding vector tool is the latest addition to IDT's broad synthetic biology portfolio, which is comprised of gene and gene fragment offerings.

Advancing CAR T-Cell Therapies with Clinical Trial Customization, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, March 25, 2024
ChromeOS, Genomics, Gene, Flow cytometry, Biomarker, Doctor of Philosophy, Clinical trial, Cytokine, CGT, Patient safety, Therapy, Cell, Pharmaceutical industry

TORONTO, March 25, 2024 /PRNewswire-PRWeb/ -- Bringing together best practices in genomics, flow cytometry, biomarkers and clinical trial operations.

Key Points: 
  • In this free webinar, learn how to successfully set up and manage highly customized CAR T-cell therapy clinical trials.
  • Introducing new CAR T-cell therapies to the market requires extensive strategizing and planning for clinical trials as well as post-marketing follow-up.
  • This webinar emphasizes the challenges encountered and the importance of customized solutions in genomics, flow cytometry, biomarkers and clinical trial operations for successful CAR T-cell therapy clinical trials.
  • Register for this webinar today to learn more about customized solutions for successful CAR T-cell therapy clinical trials.

Advanced Map of Human Blood Stem Cells Could Guide Highly Targeted Leukemia Care

Retrieved on: 
Thursday, March 21, 2024
Glycophorin A, B cell, Gene, Flow cytometry, Gene expression, Cell, AML, Mechanics, Patient, Biomarker, Research, RNA, Leukemia, Doctor of Philosophy, AUC, CD326, Antibody, Machine learning, Game theory, Blood, Hematology, Bone marrow, Atlas, Vaccine

CINCINNATI , March 21, 2024 /PRNewswire/ -- Thanks to an unusual application of game theory and machine learning technology, a large team of scientists led by experts at Cincinnati Children's has published the world's most detailed "atlas" of the many types of stem cells and early progenitors involved in producing human blood from diverse donors.

Key Points: 
  • The team has identified more than 80 distinct subsets of hematopoietic stem and progenitor cells (HSPCs) – early-stage cells that kick off production of mature red cells, white cells and other elements of our complex blood system.
  • Among the team's key findings:
    Mixing a new "cocktail" of 132 antibodies that can target surface proteins on HSPCs and related cells.
  • Testing demonstrated that the new mix outperforms commercial products for profiling human bone marrow cells.
  • One of the most immediate potential applications of the new stem cell atlas centers on how treatment centers monitor patients receiving therapies for leukemia.

SOPHiA GENETICS Announces First Homologous Recombination Deficiency (HRD) Customer in Canada

Retrieved on: 
Wednesday, March 20, 2024
Ovarian cancer, Gene, Mutation, BRCA, Genetic testing, Patient, NGS, Research, DNA, Guideline, AI, University, Cancer, Hope, Quality of life, GENETICS, Oncology, Medicine, Clinical trial, Sophia Genetics, HRD, HRR, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, March 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced the University of Saskatchewan (USask) as its first HRD customer in Canada. USask will implement the SOPHiA DDM™ Platform for use in its cutting-edge clinical trial, which aims to substantially improve the quality of life for ovarian cancer patients through expanded genetic testing. This is the first clinical trial in Canada designed to improve ovarian cancer treatment decisions and inspire guideline changes to increase access to advanced testing.

Key Points: 
  • BOSTON and ROLLE, Switzerland, March 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced the University of Saskatchewan (USask) as its first HRD customer in Canada.
  • This is the first clinical trial in Canada designed to improve ovarian cancer treatment decisions and inspire guideline changes to increase access to advanced testing.
  • It's exactly what we at SOPHiA GENETICS are working so hard to make available to clinician researchers around the world," said John Carey, Managing Director, NORAM, SOPHiA GENETICS.
  • The SOPHiA DDM™ Comprehensive Profiling Solution coupled with SOPHiA GENETICS' proprietary deep learning algorithm, GIInger™, will provide USask with a widespread look at potential mutations for each patient.

Dogs Have Been Evolving Alongside Humans for So Long, They Can Now Thrive On Plant-Based Diets, Studies Show

Retrieved on: 
Tuesday, March 19, 2024
Dicarboxylic acid, Pesticide, Health, Friends, Meat, Gene, Head, Longevity, Genetics, Research, Omnivore, Human, Protein, Carbon, AAFCO, Dog, Diet, Water, Seed, Air pollution, Family, Animal, Fertilizer, Digestion

SOUTHPORT, Conn., March 19, 2024 /PRNewswire/ -- While it's true all dogs share the wolf as a common ancestor, recent studies reveal that they no longer need to eat like one. In fact, dogs have evolved so much in their time as companions to humans that they are now classified as omnivores like humans and can flourish on a properly formulated plant-based diet. The reason, experts say, is genetics.

Key Points: 
  • In fact, dogs have evolved so much in their time as companions to humans that they are now classified as omnivores like humans and can flourish on a properly formulated plant-based diet.
  • Throughout domesticated dog evolution, they've developed ten genes that allow them to process starch-rich plant foods and thrive on omnivorous diets.
  • "We've always known dogs do well on a complete and balanced plant-based diet," says Dr. Bob Goldstein, co-founder and head of veterinary product development at Earth Animal.
  • "Over the years, we have seen friends and family raise healthy, happy, energetic, plant-based dogs.